TEMPUS ONE NOW BRINGS CLINICAL INTELLIGENCE RIGHT TO THE EHR /// LEARN MORE TEMPUS ONE NOW BRINGS CLINICAL INTELLIGENCE TO THE EHR /// LEARN MORE
04/24/2025

Tempus to Report First Quarter 2025 Financial Results on May 6

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day. 

The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus’ Investor Relations website. Alternatively, the call can be accessed via the following:

Conference ID: 4680302

Domestic Dial-in Number: (800) 715-9871

International Dial-in Number: (646) 307-1963

Live Webcast: https://edge.media-server.com/mmc/p/b4nkd33c

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. 

Contacts

Tempus Communications

Erin Carron

Erin.carron@tempus.com

Tempus Investor Relations

Elizabeth Krutoholow

Elizabeth.krutoholow@tempus.com 

Related Content

View more
  • post image
    06/09/2025

    Bridging the translational gap: The role of organoids in oncology R&D

    This white paper explores the evolving role of organoids in oncology R&D, highlighting their potential as predictive preclinical models and their ability to reduce translational risk. Download for a comprehensive overview of the scientific landscape, key adoption barriers, emerging innovations, and how pharma companies leverage organoids to accelerate precision medicine.

    Read more
  • post image
    03/25/2025

    The RNA advantage: A multimodal approach to accelerating oncology R&D

    Discover how transcriptomic data and multi-omics data integrated with AI is helping revolutionize oncology drug development and patient care and fueling precision medicine 2.0. Learn about RNA sequencing’s role in companion diagnostics and Tempus Loop’s capabilities to support target identification and validation.

    Secure your recording now.

    Watch replay
  • post image
    04/02/2025

    Development of a clinical algorithm to prognosticate response to immunotherapy

    Discover how Tempus developed and deployed the Immune Profile Score (IPS)—a powerful algorithm that provides prognostic insights into patient outcomes following treatment with immune checkpoint inhibitors (ICIs)—in ~18 months. This case study highlights the AI-driven methodology, real-world validation, and the impact of IPS in precision oncology.

    Read more